Emcure Pharmaceuticals Ltd slashed the starting dose price of its semaglutide injection

slashed the starting dose price of its semaglutide injection Poviztra® by 55% to ₹3,999 per month (from ₹8,999), with average cuts of 47% across strengths, to expand obesity treatment access amid rising demand. Q3 FY26 results (ended Dec 31, 2025) showed robust growth: domestic business +15.4% YoY led by chronic therapies like cardio/diabetes, international +12.8% YoY. Signed exclusive distribution pact with Sanofi India for oral anti-diabetic drugs to broaden reach.